Overview of Dr. Talukder
Dr. Rafee Talukder is an oncologist based in Houston, TX, specializing in genitourinary oncology, melanoma, and sarcoma. He completed his residency in internal medicine at Baylor College of Medicine in 2019 and a fellowship in hematology and medical oncology at the University of Washington in 2023. Dr. Talukder has contributed to several publications, focusing on topics like immune checkpoint inhibitors in advanced urothelial carcinoma and genomic alterations. His work has been featured in journals such as Clinical Genitourinary Cancer, BJC Reports, and Targeted Oncology.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2020 - 2023
Baylor College of MedicineResidency, Internal Medicine, 2016 - 2019
The University of Texas Health Science Center at San AntonioClass of 2016
Certifications & Licensure
TX State Medical License 2018 - 2028
SD State Medical License Active through 2027
WA State Medical License 2022 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 14 citationsOutcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.Tanya Jindal, Cindy Y Jiang, Omar Alhalabi, Charles B Nguyen, Eugene Oh
European Urology. 2026-07-01 - 1 citationsEfficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.Tanya Jindal, Cindy Y Jiang, Omar Alhalabi, Matthew Davidsohn, Dory Freeman
Urologic Oncology. 2026-01-01 - 1 citationsEfficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.Cindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, Dimitra Rafailia Bakaloudi, Rafee Talukder
The Oncologist. 2025-11-11
Abstracts/Posters
- Differential Induction Among Younger Patients Diagnosed with Secondary Acute Myelogenous Leukemia Is Feasible By Cytogenetic/Molecular Risk StratificationRafee Talukder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Superior Outcome in Elderly AML Patients Receiving Adjuvant Serotonin-Reuptake-Inhibitors during Induction61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Predictive Factors for Complete Remission and Survival in AML Patients Failing to Achieve Adequate Bone Marrow Day 14 Blast Eradication2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
